Transaction · 0001636282-26-000111

King-Jones Heidy

King-Jones Heidy, SR, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 16548.000000 shares for an estimated $1442985.60. Reported holdings after the transaction were 9451.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
SYRESpyre Therapeutics, Inc.
Trade date
Sep 01, 2026
Filing date
Sep 04, 2026
View on SEC Insider profile
Estimated value-$1.44MShares × reported price
Shares traded16.5k$87.20 per share
Holdings after9.45kDirect
% of reported position traded63.65%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 25,999 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows
SYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +10.5%1w ago +22.2%1d ago +0.4%
Returns since7d +1.8%30d +4.7%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001636282-26-000111
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 04, 2026, 01:34 AM · 3d delay
Shares
16,548 sh
$87.20 per share
Estimated value
-$1.44M
Computed from shares × price
Holdings after
9,451 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Holdings Reduction Large Sale Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

  2. F2

    Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock ac…

  3. F3

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to th…

  4. F4

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to th…

  5. F5

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to th…

  6. F6

    This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quart…

Original filing · 0001636282-26-000111
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SYRE